publicações selecionadas
-
artigo académico
- Manifestations of Anxiety, Cognition and Mood functions in the CMVMJD135 Mouse Model of MJD/SCA3. Elife. 2026
- Allosteric Modulation of Pathological Ataxin-3 Aggregation: A Path to Spinocerebellar Ataxia Type-3 Therapies. Advanced Science. 2025
- Rescue of respiratory and cognitive impairments in Rett Syndrome mice using NLX-101, a selective 5-HT1A receptor biased agonist. Biomedicine & Pharmacotherapy. 2025
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors. Cells. 2023
-
artigo de conferência
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Chemical screening for novel therapeutic target identification in Machado-Joseph disease 2022
- Pre- clinical study of a 5HT1A specific agonist in the CMVMJD135 mouse model of Machado– Joseph disease 2022
- Evaluation of antioxidant properties of Apocynum venetum 2021
- Antioxidant and neuroprotective effects of Hyptis suaveolens, Hytis pectinata and Hyptis marrubioides in Caenorhabditis elegans 2018
-
documento
- From central to peripheral perspectives in Machado-Joseph Disease: disentangling new therapeutic avenues 2025
- Novel genetic modifiers of SCA3/MJD: an EMS screening in a C. elegans model of the disease 2024
- Role of the serotonin receptor 5-HT3/LGC-50 in the suppression of Spinocerebellar Ataxia type 3 (SCA3) pathogenesis 2024
- Serotonin transporter as a modifier of proteostasis in SCA3: insights from C. elegans 2024
- Novel genetic modifiers of MJD/SCA3: an EMS screening in a C. elegans model of the disease 2024
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice" 2024
- Understanding the regulation of stress responses in a mouse model of SCA3 2024
- Repurposing dopaminergic drugs to prevent Ataxin 3 aggregation 2023
- The involvement of astrocyte calcium-dependent signaling in behavior 2023
- FastProtAct - FAST-throughput phenotypic assay to identify compounds with PROTeostasis ACTivity. 2023
- Serotonergic signaling modulation as a therapeutic approach for spinocerebellar ataxia type 3: unveiling the molecular pathways 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- Unraveling the ATXN3 interactome: clues on its contribution for physiology and disease 2023
- Identification of novel molecules with proteostasis enhancement activity using a whole-animal based fast-throughput phenotypic assay 2023
- Identification of novel molecules with proteostasis enhancement activity using a whole-animal based fast-throughput phenotypic assay. 2023
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Novel genetic modifiers of SCA3/MJD: an EMS screening in a C. elegans model of the disease 2022
- Nuclear ATXN3 DUB Physiological Substrates: Towards Understanding Their Role In The Context Of Machado-Joseph Disease 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- The involvement of astrocyte calcium-dependent signaling in behavior 2022
- Development of a high-throughput phenotypic assay to screen for chemical enhancers of proteostasis activity in Caenorhabditis elegans 2022
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Multi-modal analyses converge on the 5-HT1A serotonin receptor and CREB signaling as promising therapeutic targets for SCA3 2022
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Suppression of proteotoxic stress by serotonergic signaling 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2021
- The molecular tweezer CLR01 delay disease onset and reduce neurotoxicity in animal models of Machado-Joseph disease 2020
- Targeting of the serotonin (1A) receptor suppresses mutant ataxin-3 pathogenesis in C. elegans. 2019
- Chemogenomics screening for novel therapeutic target identification in a C. elegans model of Machado-Joseph disease 2019
- Serotonergic signaling activation suppresses proteotoxicity 2019
- NLX-112, a novel 5-HT1A receptor agonist, suppresses pathogenesis of mutant ATXN3 in C. elegans 2019
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado Joseph Disease 2019
- A neuroprotective role played by secretome from mesenchymal stem cells against the action of a-synuclein on a Caenorhabditis elegans model of Parkinson’s Disease 2019
- Early modulation of serotonergic signaling suppresses aggregation in Spinocerebellar Ataxia 3 2019
- NLX-112, a novel 5-HT1A receptor agonist, supresses neuronal dysfunction in a C. elegans model of Spinocerebellar Ataxia 2019
- Preclinical evidence supporting serotonergic modulation as a therapeutic approach for Spinocerebellar Ataxia 3 2019
- Targeting of the Serotonin (1A) Receptor Suppresses Mutant Ataxin-3 Pathogenesis in C. elegans 2019
- whole-exome sequencing of discordant and concordant affected sib pairs in spinocerebellar ataxia 3 (SCA3): a tool to identify novel modifier genes and highlight disrupted molecular pathways. 2018
- Antioxidant and neuroprotective effects of Hyptis suaveolens, Hyptis pectinata and Hyptis marrubioides in Caenorhabditis elegans. 2018
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado-Joseph disease 2018
- Preclinical evidence supporting early initiation of citalopram treatment in Machado-Joseph disease 2018
- The secretome of mesenchymal stem cells exerts a protective effect towards a Caenorhabditis Elegans model of Parkinson’s Disease 2018
- Serotonergic modulation of the proteostasis network and glutamatergic neurotransmission: impact on MJD 2017